Do You Have INFI And These 6 Other Pharma Stocks In Your Portfolio?

(RTTNews) - Infinity Pharmaceuticals Inc. (INFI) has reported encouraging monotherapy dose escalation clinical and translational data from phase 1/1b study of IPI-549 in advanced solid tumors.

The data, based on 18 patients evaluable for activity, has demonstrated a 44 percent clinical benefit rate, including one partial response in a patient with advanced peritoneal mesothelioma.

The initial results also suggest that IPI-549 treatment results in immune stimulation, with early evidence of biological activity correlating with clinical benefit, according to the Company.

In the phase 1/1b study, which involves approximately 200 patients with advanced solid tumors, IPI-549 is being evaluated as a monotherapy and in combination with Bristol Myers' Opdivo.

The study includes four parts namely, monotherapy dose escalation, monotherapy expansion, combination dose escalation and combination expansion.

The following timeline summarizes the IPI-549 program goals:

-- Report data from the monotherapy expansion component of the study in the first half of 2018. -- Report data from the combination dose-escalation component of the study in the first half of 2018. -- Report initial data from the combination expansion component of the study in the first half of 2018. -- Report additional data from at least six combination expansion cohorts, with more mature clinical and translational data, including insights from paired tumor biopsies, in the second half of 2018.

Adelene Perkins, CEO of Infinity, said that she is very pleased with how the phase 1/1b study of IPI-549 continues to progress.

INFI closed Thursday's trading at $2.80, up 11.11%.

Now, let's take a look at few other pharma stocks that grabbed headlines this week.